In the DEAP dataset, familiarity ratings were missing for three subjects, namely subjects 2, 15, and 23.
As a result, more than 25%% of the signals obtained from each of the four subjects, namely subjects 9, 11, 22, and 24 were found to be bad-channel PSD; we ignored all data from these subjects and performed analysis using only the data from the other 21 subjects.
Despite the low sample size in this pilot study, a group of subjects was identified who never smoked and were of the same gender (male), age bracket (48 to 50 years) and physique (height 185 to 191 cm and weight 75 to 85 kg), namely subjects S1 to S4 (Table 1).
Three age groups were selected in both genders, namely, subjects aged 20 35, 50 60, and 60 70 years.
Namely, subjects with the CC genotype (men and women, men, women) had higher waist circumference in comparison with subjects with other genotypes.
A control group, namely subjects from the Study on Addiction: Genetics and Environment (SAGE), was chosen because it was genotyped with Illumina Human 1M-single Infinium BeadChip (23).
Intuitively, one would expect that the rate of prevalence would be the same in a given population among various subjects; namely subjects with pyoderma, non-GAS pyoderma, PSGN cases or healthy controls.
Since Study 1 included cancers at several different sites, it was possible to constitute an additional control group for the lung cancer series, namely subjects with cancers at other sites.
We conducted this analysis on a subset of the full study population, namely, subjects with genotype data and reliable information on DBP exposures for at least 70% of years between 15 years of age and diagnosis (cases) or interview (controls).
Statistical analysis of the second derivative spectra revealed significant differences mainly between the patients with malignancy and the patients without malignancy (namely subjects without tumors and patients with benign tumors).
